急性冠脉综合征早期应用不同剂量辛伐他汀的临床观察

目的探讨急性冠状动脉综合征(ACS)早期分别应用不同剂量辛伐他汀的临床疗效和安全性。方法将113例临床确诊为ACS患者随机单盲分为两组:20mg组(A组,56例)和40mg组(B组,57例),随访8周,观察调脂疗效、药物不良反应及心脏事件的发生率。结果①两组服药后4周、8周的TC、LDL-C、hsCRP水平均较治疗前明显降低(P<0.05),B组较A组降低更明显,P<0.05;②B组累计心脏事件发生率较A组明显减少(P<0.05);③两组均无严重不良反应。结论ACS患者早期应用辛伐他汀40mg/d,能更有效地降脂,提高达标率,明显抑制炎症因子,减少心脏事件的发生率,且安全、耐受性良好。

Clinical observation on two kinds of doses of simvastatin applied early in acute coronary syndrome

Objective To observe the clinical effects and safety of early treatment with 20 mg/d and 40 mg/d Simvastatin in acute coronary Syndrome (ACS). Methods One hundred and thirteen patients with ACS were randomly divided into two groups with single blind method: a groups contained fifty and six patients administered with 20 mg/d Simvastatin, B groups contained fifty and seven patients administered with 40 mg/d Simvastatin, the levels of blood- lipid (TC, LDL, HDL, TG, hsCRP), the adverse reaction of drug and the incidence of cardiovascular disease were detected, all the patients were followed up for eight weeks. Results (1)The levels of blood-(TC, LDL,HDL,TG,hsCRP) in two groups were decreased significantly than those before treatment (P<0.05) after four and eight weeks treatment, that was decreased significantly in B group than in A one (P<0.05).(2)The incidence of cardiovascular disease in B group were less than in A group markedly (P<0.05).(3)No severe adverse effects were found in two groups. Conclusion Early treatment with 40 mg/d Simvastatin in ACS had good effects in lowing blood lipid, inhibiting the inflammatory factors, reducing the incidence of cardiovascular disease with safety and better tolerance.